USPTO serial 90757245
ADELA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 3, 2026
- Examiner
- BRECKENFELD,WILLIAM G
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ADELA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Toronto, Ontario, CA
TORONTO, ONTARIO, CA
TORONTO, ONTARIO, CA
TORONTO, ONTARIO, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ryan S. Hilbert
Ryan S. Hilbert HOLLEY & MENKER, PAPO BOX 331937ATLANTIC BEACH, FL 32233United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical diagnostic tests comprised of assays and reagents that test for the presence of medical biomarkers present in human blood and body fluids by applying advanced analytics; Medical diagnostic tests comprised of assays and reagents that test for the presence of medical biomarkers present in human blood and body fluids by applying machine learning technology; Diagnostic assays, reagents, and nucleotides for medical or clinical purposes | ACTIVE | Jul 28, 2025 |
| 010 | Blood collection kit comprised of blood collecting tubes; Blood testing apparatus; Diagnostic apparatus for medical purposes, namely, diagnostic kits consisting primarily of probes, buffers and reagents for use in liquid biopsy testing; Diagnostic tests comprising medical apparatus and instruments, namely, liquid biopsy testing systems; Medical diagnostic testing kits containing sterile medical specimen collection tools in the nature of lancets for the collection of blood for use in testing and for monitoring various medical conditions, and also including instructions and return shipping packaging; Testing kits containing medical laboratory research instruments for taking samples of human blood and body fluids for use in detecting cancer and other prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases | ACTIVE | Jul 28, 2025 |
| 042 | Providing medical research information regarding results of testing for various medical conditions; Providing scientific analysis and information regarding the results of laboratory testing in the field of various medical conditions; Laboratory testing services, namely, clinical processing of medical diagnostic testing kits; Medical research; Scientific research for medical purposes in the field of cancer and other prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases; Providing temporary use of non-downloadable software for use in creating, displaying, sharing and storing information, test results and data in the fields of cancer and other prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases; Providing online computer databases featuring medical research information in the fields of cancer and other prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases | ACTIVE | Sep 12, 2025 |
| 044 | Medical testing for diagnostic or treatment purposes; Medical diagnostic testing, monitoring, and reporting services; Consulting services in the fields of diagnostic medical testing; Providing medical information, consultancy and advisory services;Providing medical testing services and information in the fields of cancer and other prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases for diagnostic or treatment purposes; Medical testing services, namely, diagnostic testing services for detecting cancer and other prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases by identifying and analyzing biomarkers for diagnostic or treatment purposes; Providing screening, detection, and monitoring services for cancer and other prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases | ACTIVE | Sep 12, 2025 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by DNAMX Inc.
- Other trademarks owned by ADELA CANADA, INC.
- Other trademarks owned by ADELA CANADA, INC.
- Other trademarks owned by ADELA CANADA, INC.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ADELA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 3, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Feb 3, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 14, 2026 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jan 14, 2026 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Dec 3, 2025 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Dec 3, 2025 | IUAF | USE AMENDMENT FILED | — |
| Dec 3, 2025 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Oct 30, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 29, 2025 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Oct 29, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jun 2, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 1, 2025 | EXT5 | SOU EXTENSION 5 FILED | — |
| Nov 4, 2024 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Nov 4, 2024 | EXT4 | SOU EXTENSION 4 FILED | — |
| Nov 3, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 13, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 5, 2024 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jun 5, 2024 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jun 5, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 5, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 2, 2023 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Dec 2, 2023 | EXT2 | SOU EXTENSION 2 FILED | — |
| Dec 2, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 7, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 5, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jun 5, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jun 5, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 6, 2022 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 11, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 11, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 21, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 8, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 2, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 1, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 1, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 2, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 2, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 2, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 22, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 6, 2021 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Aug 27, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 9, 2021 | NWAP | NEW APPLICATION ENTERED | — |